COVID-19 diagnostic and immunologic testing should guide community reopening

  • Fang FC & al.
  • Clin Infect Dis
  • 8 Jun 2020

  • curated by Liz Scherer
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • Diagnostic testing for SARS-CoV-2 and postinfection confirmation of specific antibodies are key for local reopenings.

Why this matters

  • Familiarity with testing limitations is essential for assessing COVID-19 infections and immunity within the community, especially in light of anticipated waves.

Key points

  • RT-PCR testing assays have high analytical sensitivity (estimated limit of detection, 100-1000 copies) as well as high specificity.
  • Nasopharyngeal swab may promote patient coughing; wear appropriate personal protective equipment during testing.
    • Alternative samples: nasal, mid-turbinate, oropharyngeal swabs, and saliva; comparability relies on viral load at time of infection.
  • Negative specimens do not rule out COVID-19; repeat testing is warranted when clinical suspicion is high, especially in higher-prevalence settings.
  • PCR-positive results are possible in a range from 1 week (mild illness) to several weeks or months (severe illness) after symptom onset, although infectivity in the latter is not established.
  • Although patients may become PCR-positive after testing negative, data regarding true virological/clinical relapse are scarce.
    • Inconclusive results warrant confirmation with an alternative assay.
  • Serologic test performances vary; positive serology with a low-specificity assay likelier than not represents a false positive. 
  • IgM, IgG against SARS-CoV-2 appear as early as 3-6 days after symptom onset. 
    • Almost all patients will seroconvert by 3 weeks. 
    • Antibodies persist for at least 2 months (longer term outcomes remain unknown, given the limited time since the virus appeared).
  • Quantitative antibody titer cutoff correlating with protective immunity is currently undefined.